PN-458sc
/ Protagonist Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 25, 2026
Discovery Programs
(ACCESS Newswire)
- "Recently, Protagonist announced two new wholly owned development candidates: (i) PN-458, a novel dual GLP-GIP agonist for obesity, and (ii) PN-8047, an oral hepcidin functional mimetic complementing rusfertide, an injectable hepcidin mimetic."
New molecule • Anemia • Obesity
1 to 1
Of
1
Go to page
1